

Paxman publishes newsletter on the company's recent 77 MSEK directed share issue

Today, Paxman publishes the December issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights Paxman's directed share issue of 1,400,000 shares to existing and new shareholders, including including Creades AB (publ), Alcur Fonder and Andra AP-fonden. The proceeds from the share issue will be used to to strengthen the company's financial position and the continued work to execute on its commercialisation strategy, including the launch of a new buy-and-bill business model in the United States to enable reimbursement.

The newsletter also includes information on "Knowledge Transfer Partnership" (KPT), a new collaboration between Paxman and the University of Huddersfield to develop a novel medical device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) with financing from Innovate UK, several received orders for upgrades and new installations in the US, Europe, Asia and the Middle East, and that Paxman Scalp Cooling has been included in the new generation of an innovative mobile cancer care concept developed by the British charity Hope for Tomorrow.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxdec21en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on the company's recent 77 MSEK directed share issue](#)